SMN2 and proximal spinal muscular atrophy: Other studies have yielded successful results like Nusinersen, which is an ASO designed to treat spinal muscular atrophy (SMA), a disease caused by mutations on chromosome 5q leading to survival motor neuron (SMN) protein deficiency.